Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics, Inc. (Nasdaq: CVKD) is a clinical-stage biopharmaceutical company developing therapies for immune and thrombotic conditions. Its lead candidate, CAD-1005, is a selective 12-lipoxygenase inhibitor in development for heparin-induced thrombocytopenia; the company is preparing a pivotal Phase 3… From the company’s description.
In fiscal 2025, Cadrenal Therapeutics, Inc. reported a net loss of $13.24M. Operations used $12.60M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Cadrenal Therapeutics, Inc. does
In the company’s own words
Cadrenal Therapeutics, Inc. (Nasdaq: CVKD) is a clinical-stage biopharmaceutical company developing therapies for immune and thrombotic conditions. Its lead candidate, CAD-1005, is a selective 12-lipoxygenase inhibitor in development for heparin-induced thrombocytopenia; the company is preparing a pivotal Phase 3 trial following an end-of-Phase 2 meeting with the FDA. Its pipeline also includes tecarfarin, an oral vitamin K antagonist for chronic anticoagulation, with development focused on patients with kidney dysfunction or left ventricular assist devices, and frunexian, an intravenous Factor XIa inhibitor designed for acute-care settings. Cadrenal acquired the CAD-1005 program and related 12-LOX assets from Veralox Therapeutics in December 2025, shifting its primary strategic focus to that platform. Tecarfarin has been studied in 11 clinical trials involving more than 1,000 individuals, while frunexian is Phase 2-ready. The company’s candidates target hospital and chronic-care needs, including prevention of blood clots in patients requiring anticoagulation.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- PONTE VEDRA, FL
- Fiscal year end
- December
- CIK
- 1937993
- SIC
- 2834
Financial performance, year by year
Fiscal 2023–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Cadrenal Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Cadrenal Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Cadrenal Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Cadrenal Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Cadrenal Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”